---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-025509"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-08-04T11:52:06+00:00"
generated_at: "2026-08-04T11:55:04.606035+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CervoMed's neflamapimod gets UK Innovation Passport for DLB treatment

## Summary
- Innovation Passport awarded under UK ILAP for neflamapimod in dementia with Lewy bodies.
- Program designed to accelerate time to market and facilitate patient access in the UK.
- Provides coordinated guidance from MHRA, NHS, and HTA bodies (NICE, SMC, AWTTC).
- DLB is the second most common progressive dementia in older people in the UK; no approved treatment.
- CervoMed plans to use ILAP support to prepare for a Phase 3 trial of neflamapimod.

## SEC filing metadata
- accession: 0001437749-26-025509
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-08-04T11:52:06+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926025509/0001437749-26-025509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926025509/crvo20260803_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-025509
- JSON: https://secwatch.observer/filing/0001437749-26-025509.json
- Plain text: https://secwatch.observer/filing/0001437749-26-025509.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.